Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivomouse colon cancer model

BMC Cancer

Table 1 The effect of vitamin D analog PRI-2191 (in varied doses) alone or in combination with 5-FU on tumor growth, life span and body weight of mice bearing subcutaneous colon cancer MC38

No.	5-FU	PRI-2191	TGI [%]					ILS [%]					Maximal decrease
			TGI [%]					ILS [%]					in body weight [%]
			5-FU	PRI-2191	5-FU+	%H TGI	Effect	5-FU	PRI-2191	5-FU+	%H ILS	Effect	5-FU	PRI-2191	5-FU+
			5-FU	PRI-2191	PRI-2191	%H TGI	Effect	5-FU	PRI-2191	PRI-2191	%H ILS	Effect	5-FU	PRI-2191	PRI-2191
1	75 mg/kg;	2 μg/kg	48	6	70^*	51	Synergism	21	53	41	62	Antagonism	7	18	19
2	150 mg/kg;	2 μg/kg	87	44	96^*	92	Synergism	nt.	nt.	nt.	nt.	nt.	9	11	21
3	100 mg/kg;	1 μg/kg	38	6	51	42	Synergism	26	-6	118^*a	22	Synergism	4	6	12
4	100 mg/kg;	0.5 μg/kg	38	1	36	39	Antagonism	26	-6	43	22	Synergism	4	3	9
5	100 mg/kg;	0.25 μg/kg	38	-35	36	16	Antagonism	26	3	65	29	Synergism	4	9	9

Vitamin D analog was administered subcutaneously, three times a week.
No. – number of experiment; TGI – tumor growth inhibition; %H TGI: hypothetical tumor growth inhibition; ILS: increase in life span; %H ILS: hypothetical increase in life span; nt.: not tested; No. 1 – TGI calculated on the 27th day of the experiment, No. 2, 3, 4, 5 – TGI on the 32nd day of the experiment.
No. 1: 5-FU was injected i.p. on the first day; PRI-2191 was injected on days: 1, 3, 6, 8, 10, 13, 15, 17, 20, 22; Number of mice: control - 10; in the each treatment group - 8.
No. 2: 5-FU was injected i.p. on days: 9, 16, 23; PRI-2191 was injected on days: 11, 14, 16, 18, 21, 23; Number of mice in each group - 8.
No. 3, 4 and 5: 5-FU was injected i.v. on days: 8, 15, 30, 38; PRI-2191 was injected on days: 9, 11, 14, 16, 18, 21, 23, 25, 28, 30, 32, 35, 37, 39, 42, 44; Number of mice: No. 3, 4 and 5: control – 7; 5-FU – 7, PRI-2191 – 5; 5-FU + PRI-2191 – 6; ^* P < 0.05 as compared to control; ^*a P < 0.05 as compared to 5-FU.

ISSN: 1471-2407